INCB059872 clinical trials
Also written INCB059872.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses INCB059872 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INCB059872
- 4
Studies by the year they started
4 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses INCB059872 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02712905Written as INCB059872
- Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)TerminatedPhase 1/2Incyte CorporationNCT02959437Written as INCB059872
- A Study of INCB059872 in Relapsed or Refractory Ewing SarcomaTerminatedPhase 1Incyte CorporationNCT03514407Written as INCB059872
- A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell DiseaseTerminatedPhase 1Incyte CorporationNCT03132324Written as INCB059872
Codes
What other systems call INCB059872 · ClinicalTrials.gg INT002070
- MeSH (NLM) C000730036INCB059872One source ClinicalTrials.gov
- NCI Thesaurus C126421Lysine-specific Demethylase 1 Inhibitor INCB059872One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730036 | INCB059872 | One source ClinicalTrials.gov |
| NCI Thesaurus | C126421 | Lysine-specific Demethylase 1 Inhibitor INCB059872 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.